Proteomics International awarded $400,000 to support manufacturing capability in Australia

Proteomics International managing director Dr Richard Lipscombe said the funding would supplement the Company’s existing manufacturing strategy and budget. “It will support future manufacture of the PromarkerD test for Australia and South-East Asia by building upon Proteomics International’s specialised ISO 13485 Quality Control and Quality Assurance certification. We see enormous sales potential in this region once we complete local regulatory and reimbursement approvals. This funding will also help our activities towards obtaining TGA approval [ASX: 28 April] and registration of PromarkerD under the Medical Benefits Scheme [ASX: 22 February],” he said.

MTP Connect Announcement

ASX Release